Mark A. Velleca M.D., Ph.D.
Net Worth

Last updated:

What is Mark A. Velleca M.D., Ph.D. net worth?

The estimated net worth of Dr. Mark A. Velleca M.D., Ph.D. is at least $9,791,765 as of 8 Aug 2023. He owns shares worth $828,240 as insider, has earned $1,588,645 from insider trading and has received compensation worth at least $7,374,880 in G1 Therapeutics, Inc..

What is the salary of Mark A. Velleca M.D., Ph.D.?

Dr. Mark A. Velleca M.D., Ph.D. salary is $921,860 per year as Senior Advisor & Director in G1 Therapeutics, Inc..

How old is Mark A. Velleca M.D., Ph.D.?

Dr. Mark A. Velleca M.D., Ph.D. is 61 years old, born in 1964.

What stocks does Mark A. Velleca M.D., Ph.D. currently own?

As insider, Dr. Mark A. Velleca M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
G1 Therapeutics, Inc. (GTHX) Senior Advisor & Director 116,000 $7.14 $828,240

What does G1 Therapeutics, Inc. do?

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX logo
GTHX
G1 Therapeutics, Inc.
$7.14

Mark A. Velleca M.D., Ph.D. insider trading

G1 Therapeutics, Inc.

Dr. Mark A. Velleca M.D., Ph.D. has made 39 insider trades between 2017-2023, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of GTHX stock worth $120,540 on 8 Aug 2023.

The largest trade he's ever made was exercising 80,000 units of GTHX stock on 16 Aug 2022. As of 8 Aug 2023 he still owns at least 116,000 units of GTHX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 60,000 $2.01 $120,540
Option
Stock Option (Right to Buy) 2,714 $0.3 $814
Option
Common Stock 57,286 $0.39 $22,342
Option
Common Stock 2,714 $0.3 $814
Option
Stock Option (Right to Buy) 57,286 $0.39 $22,342
Sale
Common Stock 15,000 $11.7 $175,485
Option
Stock Option (Right to Buy) 15,000 $0.39 $5,850
Option
Common Stock 15,000 $0.39 $5,850
Option
Stock Option (Right to Buy) 20,000 $0.39 $7,800
Sale
Common Stock 20,000 $13.5 $270,040
Option
Common Stock 20,000 $0.39 $7,800
Sale
Common Stock 80,000 $12.64 $1,010,880
Option
Common Stock 80,000 $0.39 $31,200
Option
Stock Option (Right to Buy) 80,000 $0.39 $31,200
Option
Stock Options (Right to Buy) 15,000 $0.39 $5,850
Option
Common Stock 15,000 $0.39 $5,850
Option
Stock Options (Right to Buy) 40,000 $0.39 $15,600
Option
Common Stock 40,000 $0.39 $15,600
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 20,000 $0.39 $7,800
Option
Stock Options (Right to Buy) 20,000 $0.39 $7,800
Option
Stock Options (Right to Buy) 10,000 $0.39 $3,900
Sale
Common Stock 10,000 $0.39 $3,900
Option
Common Stock 10,000 $0.39 $3,900
Option
Stock Options (Right to Buy) 10,000 $0.39 $3,900
Option
Common Stock 10,000 $0.39 $3,900
Sale
Common Stock 10,000 $0.39 $3,900
Option
Common Stock 10,000 $0.39 $3,900
Option
Stock Options (Right to Buy) 10,000 $0.39 $3,900
Sale
Common Stock 10,000 $0.39 $3,900
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 11,040 N/A N/A
Sale
Common Stock 11,040 N/A N/A
Option
Stock Options (Right to Buy) 11,040 N/A N/A
Option
Common Stock 11,040 N/A N/A
Sale
Common Stock 11,040 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Stock Options (Right to Buy) 14,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 14,000 $2.06 $28,770
Option
Common Stock 14,000 N/A N/A
Option
Stock Options (Right to Buy) 14,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 3,000 N/A N/A
Option
Stock Options (Right to Buy) 3,000 N/A N/A
Option
Stock Options (Right to Buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Stock Options (Right to Buy) 9,000 N/A N/A
Option
Common Stock 9,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 5,000 N/A N/A
Option
Stock Options (Right to Buy) 5,000 N/A N/A
Option
Stock Options (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Sale
Common Stock 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Stock Options (Right to Buy) 7,500 N/A N/A

G1 Therapeutics key executives

G1 Therapeutics, Inc. executives and other stock owners filed with the SEC: